专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2474532A1 Heteroaryl sulfonamides and CCR2 审中-公开
标题翻译： Heteroarylsulfonamides和CCR2
公开(公告)号：EP2474532A1
公开(公告)日：2012-07-11
申请号：EP12162572.7
申请日：2006-01-13
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Pennell, Andrew M. K. , Punna, Sreenivas , Wei, Zheng , Wright, John Jessen , Zeng, Yibin , Badak, Arindrajit , Charvat, Trevor T. , Dairaghi, Daniel , Hanson, Derek , Jin, Jeff , Moore, Jimmie
IPC分类号： C07D213/02
CPC分类号： C07C311/21 , C07D213/48 , C07D213/61 , C07D213/643 , C07D213/70 , C07D213/73 , C07D213/76 , C07D213/79 , C07D213/81 , C07D213/89 , C07D241/22 , C07D263/32 , C07D401/04 , C07D405/04 , C07D409/12 , C07D413/06 , C07D413/10 , C07D417/12 , C07D471/04
摘要： A compound of the formula (I), or a salt thereof:

where
Ar is selected from the group consisting of substituted or unsubstituted C 6-10 aryl and substituted or unsubstituted 5- to 10-membered heteroaryl;
R 1 is selected from the group consisting of hydrogen, unsubstituted C 1 alkyl, substituted or unsubstituted C 3-8 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;
Y 1 is selected from the group consisting of -CR 2a -, -N-, and -N + (O) - -;
Y 2 is selected from the group consisting of -CR 2b -, -N-, and -N + (O) - -;
Y 3 is selected from the group consisting of -CR 2c -, -N-, and -N + (O) - -;
R 2a , R 2b , and R 2c are each independently selected from the group consisting of hydrogen, halogen, -CN, -C(O)R 3 , -CO 2 R 3 , -C(O)NR 3 R 4 , -OR 3 , - OC(O)R 3 , -OC(O)NR 3 R 4 , -SR 3 , -S(O)R 3 , -S(O) 2 R 3 , -S(O) 2 NR 3 R 4 , -NO 2 , -NR 3 R 4 , -NR 3 C(O)R 4 , -NR 3 C(O)OR 4 , -NR 3 S(O) 2 R 4 , -NR 3 C(O)NR 4 R 5 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl;
R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;
R 3 and R 4 , R 4 and R 5 or R 3 and R 5 may, together with the atoms to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered ring;
Y 4 is selected from the group consisting of -N- and -N + (O) - -;
L is selected from the group consisting of a bond, -O-, -S-, -S(O)-, S(O) 2 -, - CR 6 R 7 -, -NR 8 -, -C(O)- and -NR 8 C(O)-;
R 6 and R 7 are each independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, -CN, -OR 9 , -NR 10 R 11 , -S(O)R 9 , and -S(O) 2 R 9 ;
R 6 and R 7 may, together with the carbon atom to which they are attached, form substituted or unsubstituted C 3-8 cycloalkyl or substituted or unsubstituted 3-to 10-membered heterocyclic ring;
R 9 is selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;
R 10 and R 11 are each independently selected from the group consisting of substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted C 2-8 alkenyl, and substituted or unsubstituted C 2-8 alkynyl;
R 10 and R 11 of -NR 10 R 11 may, together with the nitrogen, form a substituted or unsubstituted C 3-8 cycloalkyl or substituted or unsubstituted 3- to 10-membered heterocyclyl;
R 8 is selected from the group consisting of hydrogen, C(O)R 12 , S(O) 2 R 12 , CO 2 R 12 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
R 12 is selected from the group consisting of substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl;
Z 1 is selected from the group consisting of substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted 3- to 10-membered heterocyclyl, and -NR 13 R 14 ;
R 13 and R 14 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted (C 1-4 alkyl)-(C 6-10 aryl), and substituted or unsubstituted (C 1-4 alkyl)-(5- to 10-membered heteroaryl);
R 13 and R 14 may, together with the nitrogen, form a substituted or unsubstituted 4-, 5-, 6-, or 7-membered heterocyclyl
with the proviso that compounds of formula CC are excluded:

where
X 14 is selected from the group consisting of -Cl, -NO 2 , -OCH 3 , -CH 3 , - NHC(O)CH 3 , and -CH 2 CH 2 -(phenyl);
R 65 is selected from the group consisting of hydrogen, substituted or unsubstituted C 1-4 alkyl, and substituted or unsubstituted -SO 2 (phenyl); and
R 60 is selected from the group consisting of -NR 61 CH 2 CH 2 OR 62 , - NR 61 CH 2 CH 2 NR 63 R 64 , -NR 61 CH 2 CH 2 SR 62 ,

where R 61 is selected from the group consisting of hydrogen and substituted or unsubstituted phenyl;
R 62 is selected from the group consisting of substituted or unsubstituted phenyl, and substituted or unsubstituted C 1-4 alkyl; and
R 63 and R 64 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted -SO 2 (phenyl), - C(O)CH 3 , -C(O)C(O)OH, and -C(O) 2 C(CH 3 ) 3 .

2. 发明授权

EP2354126B1 Heteroaryl sulfonamides and CCR2 有权转让
标题翻译：杂芳基磺酰胺和CCR2
公开(公告)号：EP2354126B1
公开(公告)日：2013-09-25
申请号：EP11002389.2
申请日：2006-01-13
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Wright, John Jessen , Zeng, Yibin , Badak, Arindrajit , Charvat, Trevor T. , Dairaghi, Daniel , Hansen, Derek , Jin, Jeff , Moore, Jimmie , Pennell, Andrew M.K. , Punna, Sreenivas , Wei, Zheng
IPC分类号： C07D213/02 , C07D401/02 , A61K31/44
CPC分类号： C07C311/21 , C07D213/48 , C07D213/61 , C07D213/643 , C07D213/70 , C07D213/73 , C07D213/76 , C07D213/79 , C07D213/81 , C07D213/89 , C07D241/22 , C07D263/32 , C07D401/04 , C07D405/04 , C07D409/12 , C07D413/06 , C07D413/10 , C07D417/12 , C07D471/04

3. 发明公开

EP2354126A1 Heteroaryl sulfonamides and CCR2 有权转让
标题翻译： Heteroarylsulfonamides和CCR2
公开(公告)号：EP2354126A1
公开(公告)日：2011-08-10
申请号：EP11002389.2
申请日：2006-01-13
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Wright, John Jessen , Zeng, Yibin , Badak, Arindrajit , Charvat, Trevor T. , Dairaghi, Daniel , Hansen, Derek , Jin, Jeff , Moore, Jimmie , Pennell, Andrew M.K. , Punna, Sreenivas , Wei, Zheng
IPC分类号： C07D213/02 , C07D401/02 , A61K31/44
CPC分类号： C07C311/21 , C07D213/48 , C07D213/61 , C07D213/643 , C07D213/70 , C07D213/73 , C07D213/76 , C07D213/79 , C07D213/81 , C07D213/89 , C07D241/22 , C07D263/32 , C07D401/04 , C07D405/04 , C07D409/12 , C07D413/06 , C07D413/10 , C07D417/12 , C07D471/04
摘要： A compound of the formula (I), or a salt thereof:

where
Ar is selected from the group consisting of substituted or unsubstituted C 6-10 aryl and substituted or unsubstituted 5- to 10-membered heteroaryl;
R 1 is selected from the group consisting of hydrogen, unsubstituted C 1 alkyl, substituted or unsubstituted C 3-8 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;
Y 1 is selected from the group consisting of -CR 2a -, -N-, and -N + (O) - -;
Y 2 is selected from the group consisting of -CR 2b -, -N-, and -N + (O) - -;
Y 3 is selected from the group consisting of -CR 2c -, -N-, and -N + (O) - -;
R 2a , R 2b , and R 2c are each independently selected from the group consisting of hydrogen, halogen, -CN, -C(O)R 3 , -CO 2 R, -C(O)NR 3 R 4 , -OR 3 , -OC(O)R 3 , -OC(O)NR 3 R 4 , -SR 3 , -S(O)R 3 , -S(O) 2 R 3 , -S(O) 2 NR 3 R 4 , -NO 2 , -NR 3 R 4 , -NR 3 C(O)R 4 , -NR 3 C(O)OR 4 , - NR 3 S(O) 2 R 4 , -NR 3 C(O)NR 4 R 5 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl;
R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;
R 3 and R 4 , R 4 and R 5 or R 3 and R 5 may, together with the atoms to which

they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered ring;

Y 4 is selected from the group consisting of -N- and -N + (O) - -;
L is selected from the group consisting of a bond, -O-, -S-, -S(O)-, S(O) 2 -, -CR 6 R 7 -, - NR 8 -, -C(O)- and -NR 8 C(O)-;
R 6 and R 7 are each independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, -CN, -OR 9 , -NR 10 R 11 , -S(O)R 9 , and -S(O) 2 R 9 ;
R 6 and R 7 may, together with the carbon atom to which they are attached, form substituted or unsubstituted C 3-8 cycloalkyl or substituted or unsubstituted 3- to 10-membered heterocyclic ring;
R 9 is selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl;
R 10 and R 11 are each independently selected from the group consisting of substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted C 2-8 alkenyl, and substituted or unsubstituted C 2-8 alkynyl;
R 10 and R 11 of -NR 10 R 11 may, together with the nitrogen, form a substituted or unsubstituted C 3-8 cycloalkyl or substituted or unsubstituted 3- to 10-membered heterocyclyl;

R 8 is selected from the group consisting of hydrogen, C(O)R 12 , S(O) 2 R 12 , CO 2 R 12 , substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
R 12 is selected from the group consisting of substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted 3- to 1 0-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl;

Z 1 is selected from the group consisting of substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted 3- to 10-membered heterocyclyl, and -NR 13 R 14 ;
R 13 and R 14 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted C 2-8 alkenyl, substituted or unsubstituted C 2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted (6 1-4 alkyl)-(C 6-10 aryl), and substituted or unsubstituted (C 1-4 alkyl)-(5- to 10-membered heteroaryl);
R 13 and R 14 may, together with the nitrogen, form a substituted or unsubstituted 4-, 5-, 6-, or 7-membered heterocyclyl
with the proviso that compounds of formula CC are excluded:

where
X 14 is selected from the group consisting of -Cl, -NO 2 , -OCH 3 , -CH 3 , -NHC(O)CH 3, and -CH 2 CH 2 -(phenyl);
R 65 is selected from the group consisting of hydrogen, substituted or unsubstituted C 1-4 alkyl, and substituted or unsubstituted -SO 2 (phenyl); and
R 60 is selected from the group consisting of -NR 61 CH 2 CH 2 OR 62 , - NR 61 CH 2 CH 2 NR 63 R 64 , -NR 61 CH 2 CH 2 SR 62 ,

where R 61 is selected from the group consisting of hydrogen and substituted or unsubstituted phenyl;
R 62 is selected from the group consisting of substituted or unsubstituted phenyl, and substituted or unsubstituted C 1-4 alkyl; and
R 63 and R 64 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-8 alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted -SO 2 (phenyl), -C(O)CH 3 , -C(O)C(O)OH, and -C(O) 2 C(CH 3 ) 3 .

4. 发明公开

EP1798223A3 Aryl sulfonamides 有权转让
标题翻译：芳基磺酰胺
公开(公告)号：EP1798223A3
公开(公告)日：2009-05-06
申请号：EP07004318.7
申请日：2003-11-17
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Wei, Zheng , Wright, J. J. , Pennell, M. K. Andrew
IPC分类号： C07D413/12 , C07D213/50 , C07D213/89 , C07D213/74 , C07D213/70 , C07D213/26 , C07D241/12 , C07D213/84 , A61K31/44 , A61P29/00
CPC分类号： C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要： Compounds of formula (I)

where L, X, Y and Z are as defined in the claims, are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulphonamide derivatives and are useful in pharmaceutical compositions and methods for the treatment of CCR9-mediated diseases.

5. 发明公开

EP2256116A3 Aryl sulfonamides 审中-公开
标题翻译：芳基磺酰胺
公开(公告)号：EP2256116A3
公开(公告)日：2011-11-16
申请号：EP10009944.9
申请日：2003-11-17
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Wei, Zheng , Wright, J.J. , Pennell, Andrew M.K.
IPC分类号： C07D213/26 , C07D213/50 , C07D213/74 , C07D213/70 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12 , A61K31/44 , A61P29/00
CPC分类号： C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要： Compounds of formula (I)

(in which the variables L, X, Y and Z are as defined in the claims) are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulphonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译：提供了式（I）化合物（其中变量L，X，Y和Z如权利要求中所定义）作为CCR9受体的有效拮抗剂，并且已经在用于炎症的动物试验中进一步证实， CCR9的标志性疾病状态。该化合物通常是芳基磺酰胺衍生物，并且可用于药物组合物，治疗CCR9介导的疾病的方法以及用于鉴定CCR9拮抗剂的分析中的对照。

6. 发明授权

EP1798223B1 Aryl sulfonamides 有权转让
标题翻译：芳基磺酰胺
公开(公告)号：EP1798223B1
公开(公告)日：2011-07-20
申请号：EP07004318.7
申请日：2003-11-17
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Wei, Zheng , Wright, J. J. , Pennell, M. K. Andrew
IPC分类号： C07D413/12 , C07D213/50 , C07D213/89 , C07D213/74 , C07D213/70 , C07D213/26 , C07D241/12 , C07D213/84 , A61K31/44 , A61P29/00
CPC分类号： C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12

7. 发明公开

EP1717583A3 Cell migration assay 审中-公开
标题翻译： Zellmigrationsassay
公开(公告)号：EP1717583A3
公开(公告)日：2007-10-10
申请号：EP06017100.6
申请日：2002-05-22
申请人： ChemoCentryx, Inc.
发明人： Wei, Zheng , Miao, Zhenhua
IPC分类号： G01N33/53 , G01N33/537 , C12N5/00 , G01N33/68
CPC分类号： G01N33/5029 , G01N33/5008 , G01N33/6863 , G01N2333/715 , G01N2500/00 , G01N2500/04
摘要： The present invention is directed to a kit for use in a modified cell migration assay allowing for improved identification and discrimination of chemokine receptor antagonists from non-specific blockers.

8. 发明授权

EP1798223B2 Aryl sulfonamides 有权转让
标题翻译：芳基磺胺
公开(公告)号：EP1798223B2
公开(公告)日：2014-07-30
申请号：EP07004318.7
申请日：2003-11-17
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Wei, Zheng , Wright, J. J. , Pennell, M. K. Andrew
IPC分类号： C07D413/12 , C07D213/50 , C07D213/89 , C07D213/74 , C07D213/70 , C07D213/26 , C07D241/12 , C07D213/84 , A61K31/44 , A61P29/00
CPC分类号： C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12

9. 发明公开

EP2256116A2 Aryl sulfonamides 审中-公开
标题翻译：芳基磺胺
公开(公告)号：EP2256116A2
公开(公告)日：2010-12-01
申请号：EP10009944.9
申请日：2003-11-17
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Wei, Zheng , Wright, J.J. , Pennell, Andrew M.K.
IPC分类号： C07D413/12 , C07D213/50 , C07D213/89 , C07D213/74 , C07D213/70 , C07D213/26 , C07D241/12 , C07D213/84 , A61K31/44 , A61P29/00
CPC分类号： C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要： Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulphonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译：提供式（I）化合物（其中变量L，X，Y和Z如权利要求中所定义）作为CCR9受体的有效拮抗剂，并且在动物实验中进一步证实为炎症，一种 CCR9的标志性疾病状态。化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR9介导的疾病的方法，以及用于鉴定CCR9拮抗剂的测定中的对照。

10. 发明公开

EP1798223A2 Aryl Sulfonamides 有权转让
标题翻译：芳基磺胺
公开(公告)号：EP1798223A2
公开(公告)日：2007-06-20
申请号：EP07004318.7
申请日：2003-11-17
申请人： ChemoCentryx, Inc.
发明人： Ungashe, Solomon , Wei, Zheng , Wright, J. J. , Pennell, M. K. Andrew
IPC分类号： C07D213/89
CPC分类号： C07C311/29 , C07C311/21 , C07C311/46 , C07C317/14 , C07D213/26 , C07D213/50 , C07D213/70 , C07D213/74 , C07D213/84 , C07D213/89 , C07D241/12 , C07D413/12
摘要： Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulphonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译：提供了其中L，X，Y和Z如权利要求中所定义的式（I）化合物，其作为CCR9受体的有效拮抗剂，并且在动物实验中进一步证实为炎症，其中一种标志性疾病 CCR9的状态。所述化合物通常为芳基磺酰胺衍生物，并且可用于治疗CCR9介导的疾病的药物组合物和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式